Analysis of Alignment Healthcare, Inc. (ALHC)
Alignment Healthcare, Inc. (ALHC) has shown some interesting price movements and technical indicators in the past few days:
1. Price Movement:
- The stock price closed at $7.88 on May 31st, after opening at $7.91. The price fluctuated between $7.79 and $8.03 during the day.
- The stock has been showing some volatility in the past few days, with price highs and lows varying significantly.
2. Technical Indicators:
- RSI Indicator: The Relative Strength Index (RSI) on May 31st was 70.32, indicating that the stock may be overbought.
- MACD Indicator: The Moving Average Convergence Divergence (MACD) showed a value of 0.51, with the MACD line crossing above the signal line, suggesting a bullish signal.
- Moving Averages: The Simple Moving Average (SMA) was at 6.736, the Exponential Moving Average (EMA) at 6.67085, and the Weighted Moving Average (WMA) at 6.96245.
3. Overall Analysis:
- The RSI being above 70 and the MACD showing a bullish signal may indicate a potential overbought situation in the stock.
- The moving averages are relatively close to each other, indicating a possible consolidation phase.
- Investors should closely monitor the stock for any signs of a reversal or continuation of the current trend.
Please note that this analysis is based on historical data and technical indicators, and it's essential to consider other factors like market conditions, news, and fundamental analysis before making any investment decisions.
Balance Sheet
These are balance sheets. Here are the conclusions:
1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $290,437,000,000 in 2023.
5. Shareholders' equity has shown variations, with the highest value in 2018 at $107,147,000,000.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.
In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.43.
Moving on to stock statistics, the company has a short ratio of 1.53, with 15.31 billion float shares and 99.29 million shares shorted. The stock outstanding is 15.33 billion shares, with 5.22% held by insiders and 57.59% held by institutions.
Valuation metrics show a PEG ratio of 26.32, forward PE of 26.32, and trailing PE of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The market capitalization is $2.92 trillion.
The stock price summary includes a beta of 1.264, 50-day moving average of $176.26, 200-day moving average of $181.04, and a 52-week range from $164.08 to $199.62.
Lastly, dividends and splits information indicates a payout ratio of 14.93%, with a dividend date on May 16, 2024. The last split date was on August 31, 2020, with a 4-for-1 split. The forward annual dividend rate is $1, with a 5-year average dividend yield of 0.73% and a trailing annual dividend yield of 0.51%.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:
- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe the following trends:
1. There was a steady increase in revenue from 2020 to 2022, with a slight decrease in 2023.
2. The company experienced significant growth in revenue between 2020 and 2022, indicating positive performance.
3. Despite the slight decrease in revenue in 2023, the company's overall revenue remains at a high level compared to 2020.
These trends suggest that the company has been successful in growing its top line over the past few years, although there was a slight dip in revenue in the most recent fiscal year.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:
1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:
1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is also an increase from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, showing growth potential in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:
1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates indicate a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:
1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It indicates a steady but slightly slower growth trajectory for the company in the near future.
Price target
The analysts' forecast for the future price of the security is as follows:
- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast of $200. However, it's important to note that there is a wide range of forecasts, from a low of $164 to a high of $250. The current price of the security is $191.57, which is below both the average and median forecasted prices.MACD of ALHC